Phase 2 Lung Cancer Trial, Not Yet Recruiting NCT06236997 Sponsor: Henan Cancer Hospital Condition: Lung Cancer
Back to Lung Cancer

Phase 2 Lung Cancer Trial, Not Yet Recruiting

NCT06236997
Not Yet Recruiting Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People aged between 18 and 75 years old.
  • People who have been diagnosed with extensive-stage small cell lung cancer (a type of lung cancer that has spread), confirmed by a tissue sample test.
  • People who are willing and able to sign a written consent form before any study-related procedures begin.
  • People who have not yet received any treatment for their extensive-stage small cell lung cancer.
  • People who have no more than 5 areas of cancer (including any spread to other parts of the body), and at least one area that can be measured using standard imaging criteria.
  • People who are expected to live for more than 3 months.
  • People who are fully active or have only minor restrictions on physical activity, as measured by a standard medical scoring tool called ECOG PS 0–1 (confirm with trial site).

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have previously received combined radiation and chemotherapy treatment for early-stage (limited-stage) small cell lung cancer.
  • People who have previously received any systemic cancer treatment or immune checkpoint inhibitor therapy (medicines that help the immune system fight cancer).
  • People who have an active autoimmune disease (where the immune system attacks the body) that has needed ongoing medical treatment in the past 2 years — note that simple hormone replacement therapies are not considered to be this type of treatment.
  • People who have active cancer spread to the brain or the lining around the brain and spinal cord, unless the brain lesions cause no symptoms and are smaller than 1 cm in size.
  • People who have cancer pressing on their spinal cord.
  • People who have cancer spread to multiple areas of the liver, except where there is only a single small affected area smaller than 2 cm.
  • People who have uncontrolled fluid build-up in body cavities (such as around the lungs, in the abdomen, or around the heart) that keeps needing to be drained.
  • People whom the trial doctors consider to be at too great a safety risk, unlikely to follow the study requirements, or whose participation would interfere with assessing the study results.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026

Contact this trial

Principal Investigator: Qimig Wang, Doctor, Henan Cancer Hospital

Phone: 0086-13783590691

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
Henan Cancer Hospital
Registry
ClinicalTrials.gov
Start date
10 February 2024
Est. completion
31 May 2026

This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.

Where this trial is recruiting

🇨🇳 China

Primary endpoints

6-m PFS rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov